GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea
This investment, on top of £3.5 million committed in 2019, will support the Global Antibiotic Research and Development Partnership (GARDP) in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as pa… read more

